Sinotherapeutics Inc. (SHA:688247)
China · Delayed Price · Currency is CNY 10.00
-0.05 (-0.50%)
At close: Dec 12, 2025
Sinotherapeutics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Net Income | 98.59 | 127.7 | 61.07 | 92.93 | 134.92 | 123.3 | Upgrade |
Depreciation & Amortization | 18.36 | 18.36 | 23.27 | 26.43 | 26.94 | 12.61 | Upgrade |
Other Amortization | 7.09 | 7.09 | 0.78 | 1.54 | 1.84 | 11.82 | Upgrade |
Loss (Gain) From Sale of Assets | - | - | -0.08 | -0.16 | 0.02 | -0.04 | Upgrade |
Asset Writedown & Restructuring Costs | -1.03 | -1.03 | 1.72 | -2.55 | 1.04 | 2.33 | Upgrade |
Loss (Gain) From Sale of Investments | -11 | -11 | -9.61 | -20.79 | -3.9 | -25.02 | Upgrade |
Stock-Based Compensation | - | - | - | - | 7.94 | 14.36 | Upgrade |
Provision & Write-off of Bad Debts | 3.93 | 3.93 | 0.81 | 1.43 | -0.29 | 1.2 | Upgrade |
Other Operating Activities | 16.66 | -2.06 | -1.22 | -5.31 | 4.25 | 13.28 | Upgrade |
Change in Accounts Receivable | -25.28 | -25.28 | -2.18 | -42.77 | -6.61 | -25.92 | Upgrade |
Change in Inventory | -16.46 | -16.46 | -56.47 | 13.83 | -0.05 | -32.41 | Upgrade |
Change in Accounts Payable | 17.53 | 17.53 | -4.11 | 12.6 | -52.23 | 98.63 | Upgrade |
Change in Other Net Operating Assets | 16.63 | 16.63 | -3.03 | -3.5 | 33.69 | - | Upgrade |
Operating Cash Flow | 119.84 | 130.23 | 12.96 | 73.18 | 145.77 | 210.04 | Upgrade |
Operating Cash Flow Growth | 89.05% | 905.01% | -82.29% | -49.80% | -30.60% | 239.76% | Upgrade |
Capital Expenditures | -85.66 | -94.93 | -38.96 | -176.34 | -16.01 | -38.34 | Upgrade |
Sale of Property, Plant & Equipment | - | - | - | - | - | 0.08 | Upgrade |
Cash Acquisitions | - | - | - | -10.85 | - | - | Upgrade |
Investment in Securities | -66 | -399.89 | -84.41 | -20 | -52.6 | 7.89 | Upgrade |
Other Investing Activities | 11.12 | 10.98 | 15.79 | 6.88 | 4.38 | 4.49 | Upgrade |
Investing Cash Flow | -140.54 | -483.84 | -107.57 | -200.31 | -64.23 | -25.89 | Upgrade |
Long-Term Debt Repaid | - | -0.07 | -0.16 | -0.92 | -0.93 | - | Upgrade |
Net Debt Issued (Repaid) | -0.07 | -0.07 | -0.16 | -0.92 | -0.93 | - | Upgrade |
Issuance of Common Stock | - | - | - | 389.93 | - | - | Upgrade |
Repurchase of Common Stock | -36.15 | -36.15 | - | - | - | - | Upgrade |
Common Dividends Paid | -27.84 | -27.88 | -28.11 | - | - | - | Upgrade |
Other Financing Activities | 36.15 | - | - | -13.36 | - | - | Upgrade |
Financing Cash Flow | -27.91 | -64.09 | -28.27 | 375.65 | -0.93 | - | Upgrade |
Foreign Exchange Rate Adjustments | 0.07 | 1.71 | 1.52 | 2.97 | -2.9 | -8.29 | Upgrade |
Net Cash Flow | -48.54 | -416 | -121.36 | 251.5 | 77.71 | 175.86 | Upgrade |
Free Cash Flow | 34.18 | 35.3 | -26 | -103.15 | 129.77 | 171.7 | Upgrade |
Free Cash Flow Growth | 597.37% | - | - | - | -24.42% | 350.13% | Upgrade |
Free Cash Flow Margin | 7.11% | 6.90% | -8.67% | -41.67% | 41.13% | 53.80% | Upgrade |
Free Cash Flow Per Share | 0.07 | 0.08 | -0.06 | -0.24 | 0.32 | 0.42 | Upgrade |
Cash Income Tax Paid | 21.09 | 5.13 | 1.28 | 9.17 | 1.1 | 10.35 | Upgrade |
Levered Free Cash Flow | 7.13 | -22.06 | -42.85 | -150.44 | 30.86 | 118.34 | Upgrade |
Unlevered Free Cash Flow | 7.13 | -22.06 | -42.82 | -150.31 | 31.01 | 118.34 | Upgrade |
Change in Working Capital | -12.76 | -12.76 | -63.78 | -20.34 | -26.98 | 56.21 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.